Aeroscena® Labs Opens Essential Oil Clinical Research and Development Assets to the Public

Posted by Mark Kohoot on


Aeroscena®, the global leader in the research and development of medically-recognized clinical aromatherapy formulas, has opened up its essential oil R&D capabilities to the public. These assets include fMRI, MC/GC testing and clinical trial support, resulting in the first contract research organization of its kind to focus on essential oils.


Aeroscena®, the recognized leader in evidence-based clinical aromatherapy, is opening its essential oil research and development assets to the public.

The company is now able to offer a broad range of services ranging from purity and quality testing, to fMRI and full clinical trial support in cooperation with their multiple health care partners.

"We made the decision to offer our services as a contract research organization specializing in essential oils in order to help further the scientific reach of aromatherapy, and therefore its acceptance within the medical community," says Aeroscena®'s founder and CEO, Mark Kohoot. "It's unfortunate that so much misinformation and even deception exists about the effects and efficacy of essential oils. Our aim is to be part of the solution and path forward, changing the thinking around research-based aromatherapy as an accepted treatment modality whenever there is credible, scientific evidence to do so."


Clinical Research Capabilities

Aeroscena, located on the campus of the world-renown Cleveland Clinic, has established relationships with multiple research centers and hospitals throughout the United States and Europe. This has given the company unprecedented access to research and testing facilities that most organizations would not be able to access on their own. Offerings include but are not limited to:

Functional Magnetic Resistance Imaging (fMRI) for measurement of brain activity and response to essential oil and aromatherapy exposure by detecting changes associated with cerebral blood flow and neuronal activation. Aeroscena® will be able to carry out pre-designed studies, or design custom studies to examine human response.

Mass Spectrometry (MS) analysis of essential oils to determine their composition. MS testing ionizes chemical species and sorts the ions based on their mass-to-charge ratio within a given sample. Resulting MS data can then be benchmarked against source data or other standards.

Gas Chromatography (GC) analysis carried out by gas chromatograph, enabling the identification of specific molecules present in a given essential oil or oil blend. GC testing can be used to verify that a given set of expected essential oil constituents are present, or to identify adulterants, synthetic additives and chemical residues from fertilizers and pesticides.

Clinical trial support including single lab and multi-site clinical trials for both national and international organizations, assistance with selection of clinical sites and implementation of clinical protocols.

Regulatory services that address research design and compliance in accordance with IRB and federal requirements.


To learn more about Aeroscena®'s commitment to essential oil research and the science of clinical aromatherapy, please see:


Click to download the press release in its entirety.


About Aeroscena®, LLC: 

Established in 2010, Aeroscena® is the parent company and research and development division behind Ascents® Clinical Aromatherapy formulas. Ascents® formulas are the only aromatherapy products that are recommended by doctors, used by hospitals®. Aeroscena® is located on the campus of the Cleveland Clinic in Cleveland, OH. For more information about Ascents®, visit For more information about Aeroscena®, visit

Older Post Newer Post